Skip Navigation
Skip to contents

Diabetes Metab J : Diabetes & Metabolism Journal

Search
OPEN ACCESS

Author index

Page Path
HOME > Browse > Author index
Search
Hak Yeon Bae  (Bae HY) 3 Articles
Others
Comparison of Vildagliptin and Pioglitazone in Korean Patients with Type 2 Diabetes Inadequately Controlled with Metformin
Jong Ho Kim, Sang Soo Kim, Hong Sun Baek, In Kyu Lee, Dong Jin Chung, Ho Sang Sohn, Hak Yeon Bae, Mi Kyung Kim, Jeong Hyun Park, Young Sik Choi, Young Il Kim, Jong Ryeal Hahm, Chang Won Lee, Sung Rae Jo, Mi Kyung Park, Kwang Jae Lee, In Joo Kim
Diabetes Metab J. 2016;40(3):230-239.   Published online April 5, 2016
DOI: https://doi.org/10.4093/dmj.2016.40.3.230
  • 5,164 View
  • 48 Download
  • 13 Web of Science
  • 13 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   
Background

We compared the efficacies of vildagliptin (50 mg twice daily) relative to pioglitazone (15 mg once daily) as an add-on treatment to metformin for reducing glycosylated hemoglobin (HbA1c) levels in Korean patients with type 2 diabetes.

Methods

The present study was a multicenter, randomized, active-controlled investigation comparing the effects of vildagliptin and pioglitazone in Korean patients receiving a stable dose of metformin but exhibiting inadequate glycemic control. Each patient underwent a 16-week treatment period with either vildagliptin or pioglitazone as an add-on treatment to metformin.

Results

The mean changes in HbA1c levels from baseline were –0.94% in the vildagliptin group and –0.6% in the pioglitazone group and the difference between the treatments was below the non-inferiority margin of 0.3%. The mean changes in postprandial plasma glucose (PPG) levels were –60.2 mg/dL in the vildagliptin group and –38.2 mg/dL in the pioglitazone group and these values significantly differed (P=0.040). There were significant decreases in the levels of total, low density lipoprotein, high density lipoprotein (HDL), and non-HDL cholesterol in the vildagliptin group but increases in the pioglitazone group. The mean change in body weight was –0.07 kg in the vildagliptin group and 0.69 kg in the pioglitazone group, which were also significantly different (P=0.002).

Conclusion

As an add-on to metformin, the efficacy of vildagliptin for the improvement of glycemic control is not inferior to that of pioglitazone in Korean patients with type 2 diabetes. In addition, add-on treatment with vildagliptin had beneficial effects on PPG levels, lipid profiles, and body weight compared to pioglitazone.

Citations

Citations to this article as recorded by  
  • Factors contributing to the adverse drug reactions associated with the dipeptidyl peptidase-4 (DPP-4) inhibitors: A scoping review
    Swetha R. Reghunath, Muhammed Rashid, Viji Pulikkel Chandran, Girish Thunga, K.N. Shivashankar, Leelavathi D. Acharya
    Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2023; 17(7): 102790.     CrossRef
  • Efficacy and safety of evogliptin in patients with type 2 diabetes and non‐alcoholic fatty liver disease: A multicentre, double‐blind, randomized, comparative trial
    Eugene Han, Ji Hye Huh, Eun Y. Lee, Ji C. Bae, Sung W. Chun, Sung H. Yu, Soo H. Kwak, Kyong S. Park, Byung‐Wan Lee
    Diabetes, Obesity and Metabolism.2022; 24(4): 752.     CrossRef
  • A double‐blind, Randomized controlled trial on glucose‐lowering EFfects and safety of adding 0.25 or 0.5 mg lobeglitazone in type 2 diabetes patients with INadequate control on metformin and dipeptidyl peptidase‐4 inhibitor therapy: REFIND study
    Soree Ryang, Sang Soo Kim, Ji Cheol Bae, Ji Min Han, Su Kyoung Kwon, Young Il Kim, Il Seong Nam‐Goong, Eun Sook Kim, Mi‐kyung Kim, Chang Won Lee, Soyeon Yoo, Gwanpyo Koh, Min Jeong Kwon, Jeong Hyun Park, In Joo Kim
    Diabetes, Obesity and Metabolism.2022; 24(9): 1800.     CrossRef
  • The rs12617336 and rs17574 Dipeptidyl Peptidase-4 Polymorphisms Are Associated With Hypoalphalipoproteinemia and Dipeptidyl Peptidase-4 Serum Levels: A Case-Control Study of the Genetics of Atherosclerotic Disease (GEA) Cohort
    Gilberto Vargas-Alarcón, María del Carmen González-Salazar, Christian Vázquez-Vázquez, Adrián Hernández-Díaz Couder, Fausto Sánchez-Muñoz, Juan Reyes-Barrera, Sergio A. Criales-Vera, Marco Sánchez-Guerra, Citlalli Osorio-Yáñez, Rosalinda Posadas-Sánchez
    Frontiers in Genetics.2021;[Epub]     CrossRef
  • Reduction in HbA1c with SGLT2 inhibitors vs. DPP-4 inhibitors as add-ons to metformin monotherapy according to baseline HbA1c: A systematic review of randomized controlled trials
    A.J. Scheen
    Diabetes & Metabolism.2020; 46(3): 186.     CrossRef
  • Combination Therapy of Oral Hypoglycemic Agents in Patients with Type 2 Diabetes Mellitus
    Min Kyong Moon
    The Journal of Korean Diabetes.2018; 19(1): 23.     CrossRef
  • Comparative Cardiovascular Risks of Dipeptidyl Peptidase-4 Inhibitors: Analyses of Real-world Data in Korea
    Kyoung Hwa Ha, Bongseong Kim, Hae Sol Shin, Jinhee Lee, Hansol Choi, Hyeon Chang Kim, Dae Jung Kim
    Korean Circulation Journal.2018; 48(5): 395.     CrossRef
  • Safety and efficacy of low dose pioglitazone compared with standard dose pioglitazone in type 2 diabetes with chronic kidney disease: A randomized controlled trial
    Bancha Satirapoj, Khanin Watanakijthavonkul, Ouppatham Supasyndh, Stephen L Atkin
    PLOS ONE.2018; 13(10): e0206722.     CrossRef
  • Combination therapy of oral hypoglycemic agents in patients with type 2 diabetes mellitus
    Min Kyong Moon, Kyu Yeon Hur, Seung-Hyun Ko, Seok-O Park, Byung-Wan Lee, Jin Hwa Kim, Sang Youl Rhee, Hyun Jin Kim, Kyung Mook Choi, Nan-Hee Kim
    The Korean Journal of Internal Medicine.2017; 32(6): 974.     CrossRef
  • Combination Therapy of Oral Hypoglycemic Agents in Patients with Type 2 Diabetes Mellitus
    Min Kyong Moon, Kyu-Yeon Hur, Seung-Hyun Ko, Seok-O Park, Byung-Wan Lee, Jin Hwa Kim, Sang Youl Rhee, Hyun Jin Kim, Kyung Mook Choi, Nan-Hee Kim
    Diabetes & Metabolism Journal.2017; 41(5): 357.     CrossRef
  • Efficacy and safety of adding evogliptin versus sitagliptin for metformin‐treated patients with type 2 diabetes: A 24‐week randomized, controlled trial with open label extension
    Sang‐Mo Hong, Cheol‐Young Park, Dong‐Min Hwang, Kyung Ah Han, Chang Beom Lee, Choon Hee Chung, Kun‐Ho Yoon, Ji‐Oh Mok, Kyong Soo Park, Sung‐Woo Park
    Diabetes, Obesity and Metabolism.2017; 19(5): 654.     CrossRef
  • Antihyperglycemic agent therapy for adult patients with type 2 diabetes mellitus 2017: a position statement of the Korean Diabetes Association
    Seung-Hyun Ko, Kyu-Yeon Hur, Sang Youl Rhee, Nan-Hee Kim, Min Kyong Moon, Seok-O Park, Byung-Wan Lee, Hyun Jin Kim, Kyung Mook Choi, Jin Hwa Kim
    The Korean Journal of Internal Medicine.2017; 32(6): 947.     CrossRef
  • Antihyperglycemic Agent Therapy for Adult Patients with Type 2 Diabetes Mellitus 2017: A Position Statement of the Korean Diabetes Association
    Seung-Hyun Ko, Kyu-Yeon Hur, Sang Youl Rhee, Nan-Hee Kim, Min Kyong Moon, Seok-O Park, Byung-Wan Lee, Hyun Jin Kim, Kyung Mook Choi, Jin Hwa Kim
    Diabetes & Metabolism Journal.2017; 41(5): 337.     CrossRef
Response: Clinical Marker of Platelet Hyperreactivity in Diabetes Mellitus (Diabetes Metab J 2013;37:423-8)
Jin Hwa Kim, Hak Yeon Bae, Sang Yong Kim
Diabetes Metab J. 2014;38(2):160-161.   Published online April 18, 2014
DOI: https://doi.org/10.4093/dmj.2014.38.2.160
  • 3,164 View
  • 29 Download
  • 4 Web of Science
  • 4 Crossref
PDFPubReader   

Citations

Citations to this article as recorded by  
  • Impact of Uncontrolled Diabetes Mellitus on Blood Cells Indices and Plasma Components in Patients Without Nephropathy
    Hisham Ali Waggiallah, Hala Elsir Khair, Rania Saad Suliman, Humood Al Shmrany, Elturabi Elsayed Elkhider, Mudathir Mohamed Ahmed Eltayeb, Nermen Abdelftah Mohamed Ma, Yousif Mohammed Elmosaad
    Pakistan Journal of Biological Sciences.2023; 26(5): 279.     CrossRef
  • Effects of statin therapy on mean platelet volume in patients with risk of cardiovascular diseases: a systematic review and meta-analysis
    Shuaifei Ji, Babo Zhang, Xianda Wang, Heng Shi, Lixin Yu, Xiaocheng Wang
    Bioscience Reports.2019;[Epub]     CrossRef
  • The relationship between mean platelet volume and diabetic retinopathy: a systematic review and meta-analysis
    ShuaiFei Ji, Jie Zhang, XiuDe Fan, XiQiang Wang, XiaoNa Ning, BaBo Zhang, Heng Shi, Hong Yan
    Diabetology & Metabolic Syndrome.2019;[Epub]     CrossRef
  • Platelets volume indexes and cardiovascular risk factors
    Thaís Resende Batista, Roberta Carvalho de Figueiredo, Danyelle Romana Alves Rios
    Revista da Associação Médica Brasileira.2018; 64(6): 554.     CrossRef
Clinical Marker of Platelet Hyperreactivity in Diabetes Mellitus
Jin Hwa Kim, Hak Yeon Bae, Sang Yong Kim
Diabetes Metab J. 2013;37(6):423-428.   Published online December 12, 2013
DOI: https://doi.org/10.4093/dmj.2013.37.6.423
  • 4,308 View
  • 52 Download
  • 26 Crossref
AbstractAbstract PDFPubReader   

Atherothrombotic complications are important causes of morbidity and mortality in diabetic patients. Diabetes has been considered to be a prothrombotic status. Several factors contribute to the prothrombotic condition, such as increasing coagulation, impaired fibrinolysis, endothelial dysfunction, and platelet hyperreactivity. Among the factors that contribute to the prothrombotic status in diabetes, altered platelet function plays a crucial role. Although understanding platelet function abnormalities in diabetes still remains as a challenge, more attention should be focused on platelet function for effective management and the prediction of atherothrombotic events in diabetic patients. This review will provide an overview on the current status of knowledge of platelet function abnormalities and clinical marker of platelet hyperreactivity in patients with diabetes.

Citations

Citations to this article as recorded by  
  • Prediction of type 2 diabetes mellitus using hematological factors based on machine learning approaches: a cohort study analysis
    Amin Mansoori, Toktam Sahranavard, Zeinab Sadat Hosseini, Sara Saffar Soflaei, Negar Emrani, Eisa Nazar, Melika Gharizadeh, Zahra Khorasanchi, Sohrab Effati, Mark Ghamsary, Gordon Ferns, Habibollah Esmaily, Majid Ghayour Mobarhan
    Scientific Reports.2023;[Epub]     CrossRef
  • Platelet P2Y1 receptor exhibits constitutive G protein signaling and β-arrestin 2 recruitment
    Agnès Ribes, Cédric Garcia, Marie-Pierre Gratacap, Evi Kostenis, Laurent O. Martinez, Bernard Payrastre, Jean-Michel Sénard, Céline Galés, Véronique Pons
    BMC Biology.2023;[Epub]     CrossRef
  • Sex differences in the relationship between platelet count and type 2 diabetes risk in community‐dwelling adults: Longitudinal findings over 14 years
    Eun Kyeong Yun, In‐Ho Seo, Hye Sun Lee, So‐Young Seol, Yong‐Jae Lee
    Diabetes/Metabolism Research and Reviews.2023;[Epub]     CrossRef
  • Platelet Glycoprotein-Ib (GPIb) May Serve as a Bridge between Type 2 Diabetes Mellitus (T2DM) and Atherosclerosis, Making It a Potential Target for Antiplatelet Agents in T2DM Patients
    Muttia Amalia, Meidi Utami Puteri, Fadlina Chany Saputri, Rani Sauriasari, Bambang Widyantoro
    Life.2023; 13(7): 1473.     CrossRef
  • Effect of oral versus parenteral vitamin D3 supplementation on nuclear factor-κB and platelet aggregation in type 2 diabetic patients
    Esraa Habiba, Samia Ali, Yehia Ghanem, Ola Sharaki, Wafaa Hewedy
    Canadian Journal of Physiology and Pharmacology.2023; 101(11): 610.     CrossRef
  • Characteristics of cerebral ischemic stroke based on moyamoya disease and atherosclerosis-associated intracranial arterial stenosis
    Zhiying Chen, Xiaoqin Wu, Da Zhou, Shuling Shang, Yuchuan Ding, Xunming Ji, Ran Meng
    Neurological Sciences.2022; 43(2): 1087.     CrossRef
  • Basic Coagulation Profiles and Platelet Parameters Among Adult Type 1 and Type 2 Diabetes Patients at Dessie Referral Hospital, Northeast Ethiopia: Comparative Cross-Sectional Study
    Hussen Ebrahim, Fikir Asrie, Zegeye Getaneh
    Journal of Blood Medicine.2021; Volume 12: 33.     CrossRef
  • Magnetic fields as a potential therapy for diabetic wounds based on animal experiments and clinical trials
    Huanhuan Lv, Junyu Liu, Chenxiao Zhen, Yijia Wang, Yunpeng Wei, Weihao Ren, Peng Shang
    Cell Proliferation.2021;[Epub]     CrossRef
  • Diabetes and hypertension: Pivotal involvement of purinergic signaling
    Karine Paula Reichert, Milagros Fanny Vera Castro, Charles Elias Assmann, Nathieli Bianchin Bottari, Vanessa Valéria Miron, Andréia Cardoso, Naiara Stefanello, Vera Maria Melchiors Morsch, Maria Rosa Chitolina Schetinger
    Biomedicine & Pharmacotherapy.2021; 137: 111273.     CrossRef
  • The hemostatic parameters in pregnant women with different types of diabetes mellitus
    R. V. Kapustin, E. V. Kopteeva, O. N. Arzhanova, A. V. Tiselko, N. Е. Androsova, T. I. Oparina
    Diabetes mellitus.2021; 24(3): 251.     CrossRef
  • Comparison of the progressive changes in hemogram parameters of normal glycemic and gestational diabetic patients throughout the first two trimesters and predictive ability of these indices for gestational diabetes mellitus
    Pelin AYTAN, Seyran BOZKURT BABUŞ, Özde SAKARYA, Revan Sabri ÇİFTÇİ, Kasım AKAY, Hakan AYTAN
    Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi.2020; 17(4): 533.     CrossRef
  • A Pilot Study on the Effect of Anti-Thrombopoietin Antibody on Platelet Count in Patients with Type 2 Diabetes
    Takuya Fukuda, Masahide Hamaguchi, Takafumi Osaka, Yoshitaka Hashimoto, Emi Ushigome, Mai Asano, Masahiro Yamazaki, Eriko Fukuda, Kei Yamaguchi, Koji Ogawa, Naoki Goshima, Michiaki Fukui
    Molecules.2020; 25(7): 1667.     CrossRef
  • Patient with diabetes after acute coronary event. How to improve forecast?
    O. L. Barbarash
    Medical alphabet.2019; 1(3): 6.     CrossRef
  • Enhanced Platelet Sensitivity to IGF-1 in Patients with Type 2 Diabetes Mellitus
    N. Gligorijevic, D. Robajac, O. Nedic
    Biochemistry (Moscow).2019; 84(10): 1213.     CrossRef
  • Comprehensive Quality Control of the Regenerative Therapy Using Platelet Concentrates: The Current Situation and Prospects in Japan
    Tomoyuki Kawase, Kazuhiro Okuda
    BioMed Research International.2018; 2018: 1.     CrossRef
  • Changes in platelet morphology indices in relation to duration of disease and glycemic control in children with type 1 diabetes mellitus
    Vybhav Venkatesh, Rakesh Kumar, Dinesh Kumar Varma, Prateek Bhatia, Jaivinder Yadav, Devi Dayal
    Journal of Diabetes and its Complications.2018; 32(9): 833.     CrossRef
  • Quantifying Platelet Margination in Diabetic Blood Flow
    Hung-Yu Chang, Alireza Yazdani, Xuejin Li, Konstantinos A.A. Douglas, Christos S. Mantzoros, George Em Karniadakis
    Biophysical Journal.2018; 115(7): 1371.     CrossRef
  • Redox Proteomics and Platelet Activation: Understanding the Redox Proteome to Improve Platelet Quality for Transfusion
    Giona Sonego, Mélanie Abonnenc, Jean-Daniel Tissot, Michel Prudent, Niels Lion
    International Journal of Molecular Sciences.2017; 18(2): 387.     CrossRef
  • Farnesoid X Receptor and Liver X Receptor Ligands Initiate Formation of Coated Platelets
    Amanda J. Unsworth, Alexander P. Bye, Dionne S. Tannetta, Michael J.R. Desborough, Neline Kriek, Tanya Sage, Harriet E. Allan, Marilena Crescente, Parveen Yaqoob, Timothy D. Warner, Chris I. Jones, Jonathan M. Gibbins
    Arteriosclerosis, Thrombosis, and Vascular Biology.2017; 37(8): 1482.     CrossRef
  • Aspirin in the prevention of cardiovascular events in patients with diabetes
    David S. H. Bell
    Postgraduate Medicine.2016; 128(2): 180.     CrossRef
  • ROLE OF NITRIC OXIDE METABOLITES WITHIN THE IMPACT OF THE SUB-TOXIC SUCCINAMIDES DOSES ON STATE OF HEMOSTASIS
    I.А. Palagina, M.Y. Kudria, О.S. Lаlymеnkо
    Fiziolohichnyĭ zhurnal.2016; 62(6): 34.     CrossRef
  • Influence of genetic variations in platelet glycoproteins and eNOS in the development of arterial ischaemia of lower limbs in type 2 diabetes mellitus patients
    Virginia Carvalhais, Ema Ruivães, Luis Bernardo Pina-Cabral, Bárbara Mesquita, Flávio Oliveira, Maria Céu Monteiro, Maria Begoña Criado
    The Foot.2016; 29: 42.     CrossRef
  • Circulating endothelial progenitor cells and angiogenic factors in diabetes complicated diabetic foot and without foot complications
    Arleta Kulwas, Ewelina Drela, Wiesław Jundziłł, Barbara Góralczyk, Barbara Ruszkowska-Ciastek, Danuta Rość
    Journal of Diabetes and its Complications.2015; 29(5): 686.     CrossRef
  • Cerebrovascular diseases: perspectives of pathogenetic metabolic haemangiocorrective treatment
    M. M. Tanashyan, O. V. Lagoda, K. V. Antonova
    Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova.2015; 115(9): 70.     CrossRef
  • Letter: Clinical Marker of Platelet Hyperreactivity in Diabetes Mellitus (Diabetes Metab J2013;37:423-8)
    Cengiz Beyan, Esin Beyan
    Diabetes & Metabolism Journal.2014; 38(2): 158.     CrossRef
  • Response: Clinical Marker of Platelet Hyperreactivity in Diabetes Mellitus (Diabetes Metab J2013;37:423-8)
    Jin Hwa Kim, Hak Yeon Bae, Sang Yong Kim
    Diabetes & Metabolism Journal.2014; 38(2): 160.     CrossRef

Diabetes Metab J : Diabetes & Metabolism Journal